In a recent report, EF Hutton reaffirmed its buy recommendation for Replimune Group (NASDAQ:REPL). An average price target of $53.15 represents a potential upside of 176.70% from the current stock price of $19.21, according to Fintel.
As of May 11, 2023, Replimune Group’s projected annual revenue stands at $15 million while the projected annual non-GAAP EPS is -$3.43. There are currently 351 funds or institutions reporting positions in Replimune Group, an increase of 40 owner(s) or 12.86% in the last quarter. The put/call ratio of REPL is 0.06, indicating a bullish outlook.
Price T Rowe Associates owns 5,496K shares of Replimune Group, representing 9.70% ownership of the company. Baker Bros. Advisors holds 4,578K shares or 8.08%, while Redmile Group owns 3,812K shares, representing 6.73% ownership of the company. Omega Fund Management owns 3,050K shares or 5.38% ownership of the company.
Replimune Group, headquartered in Woburn, MA, is focused on developing the next generation of oncolytic immune-gene therapies for cancer treatment. Its Immulytic™ platform is designed to activate the immune system and maximize tumor cell killing and the delivery of immune-activating proteins directly to the tumor and lymph nodes. The company plans to progress these therapies rapidly through clinical development in combination with other immuno-oncology products to treat a broad range of cancers.
For more information about Replimune Group and to keep up with the latest news, see Fintel’s coverage.
The opinions and views expressed herein are those of the author and do not necessarily represent those of Nasdaq, Inc.
